AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36470745
Drug: Non-opioid analgesics
RxNorm normalized name: Non-opioid analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid analgesics before end of surgery
Trial: 36470745
Drug: Opioid doses
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid doses
Trial: 36470974
Drug: PAC-1 at
RxNorm normalized name: PAC-1
DrugBank: PAC-1 (DB13048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC-1 at 750 mg/day
Trial: 36471059
Drug: Colon capsule
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon capsule endoscopy (CCE) as an alternative to CT colonography
Trial: 36471059
Drug: Colon capsule
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon capsule endoscopy (CCE) as an alternative to AA colonoscopy
Trial: 36471142
Drug: Protamine administration
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine administration at a rate of 25 mg·min
Trial: 36471142
Drug: Protamine:heparin ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine:heparin ratio of 0.3
Trial: 36471142
Drug: Protamine:heparin ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine:heparin ratio of 0.5
Trial: 36471222
Drug: Single 300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 300-mg oral dose of tucatinib
Trial: 36471253
Drug: Capsaicin 8%
RxNorm normalized name: CAPSAICIN 8% PATCH KIT,4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin 8% (Qutenza®) patch applied at three time intervals
Trial: 36471891
Drug: Trauma-informed yoga
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-informed yoga intervention (6-week, twice-weekly sessions)
Trial: 36472134
Drug: zolpidem tartrate
RxNorm normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zolpidem tartrate extended-release 6.25 mg
Trial: 36472300
Drug: High-specific-activity I-131
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-specific-activity I-131 meta-iodobenzylguanidine (dose: ~18.5 GBq (~500 mCi))
Trial: 36472579
Drug: exercise treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exercise treatment
Trial: 36472579
Drug: liraglutide treatment
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liraglutide treatment
Trial: 36472719
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation (OAC) treatment including direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA)
Trial: 36472719
Drug: OAC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC therapy in anaemic patients
Trial: 36472728
Drug: Relugolix (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix (loading dose 360 mg at Day -14, then 120 mg/day until Day -1; followed by 120 mg/day with apalutamide 240 mg from Day 1 to Day 28)
Trial: 36472728
Drug: Relugolix +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix + Apalutamide (120 mg/day of relugolix with 240 mg of apalutamide from Day 1 to Day 28)
Trial: 36472728
Drug: Relugolix monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix monotherapy
Trial: 36472876
Drug: Elaboration on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elaboration on common errors in patient treatment combined with individualized mailed feedback
Trial: 36472904
Drug: Call for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Call for Life Uganda (CFLU) interactive voice response tool providing daily pill reminders, preappointment reminders, symptom reporting, and health promotion tips.
Trial: 36473121
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg loading dose followed by 0.5 mg/day until discharge) plus atorvastatin 80 mg
Trial: 36473121
Drug: Colchicine plus
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine plus atorvastatin
Trial: 36473633
Drug: Tralokinumab treatment
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tralokinumab treatment
Trial: 36474017
Drug: Leucine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucine (2 g)
Trial: 36474266
Drug: Higher daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher daily AChE levels
Trial: 36474435
Drug: c.1342C>G, g.41635A>G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c.1342C>G, g.41635A>G and c.2699C>T polymorphisms
Trial: 36474510
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (group M)
Trial: 36475114
Drug: Dexamethasone 0.2
RxNorm normalized name: dexamethasone 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.2 mg/kg intravenously daily (n = 70)
Trial: 36475114
Drug: Dexamethasone 6
RxNorm normalized name: dexamethasone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 6 mg daily (n = 72)
Trial: 36476135
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg once daily for 17 weeks
Trial: 36476605
Drug: Telemonitoring group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring group using continuous glucose monitor (CGM), insulin pen, activity tracker, and smartphone applications.
Trial: 36476605
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care group using blinded CGM for the first and last 20 days and a blinded insulin pen for the entire period.
Trial: 36477458
Drug: Early ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early ibuprofen treatment
Trial: 36477870
Drug: Avapritinib 300
RxNorm normalized name: avapritinib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avapritinib 300 mg once daily orally
Trial: 36477975
Drug: Azacitidine monotherapy
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine monotherapy
Trial: 36478334
Drug: Zolbetuximab 800
RxNorm normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolbetuximab 800 mg/m² intravenous
Trial: 36479110
Drug: CCRT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT treatment
Trial: 36479231
Drug: CPI-613 (devimistat)
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPI-613 (devimistat) combined with radiation therapy (RT)
Trial: 36479375
Drug: Offering continual
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Offering continual social services as a potential solution.
Trial: 36480111
Drug: Phenylephrine HCl
RxNorm normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine HCl (2.5 to 10 mg)
Trial: 36480388
Drug: E-CPTs with
RxNorm normalized name: E-Z Scrub with Ultradex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-CPTs with 1 mL price-frame
Trial: 36480395
Drug: Behavioral economic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral economic measure drug demand
Trial: 36480395
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of drug demand and LPP
Trial: 36480452
Drug: Oxytocin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (0.5 to 5 IU administered as an intravenous bolus over 1 minute)
Trial: 36480463
Drug: Endogenous secretory
RxNorm normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endogenous secretory leukocyte protease inhibitor (SLPI)
Trial: 36481736
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg intravenously on day 1 of each 3-week cycle plus famitinib 20 mg orally once daily
Trial: 36482076
Drug: Gelofusine® (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelofusine® (40 mg/ml)
Trial: 36482188
Drug: Re-irradiation with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-irradiation with a schedule of 3 Gray per fraction (minimum 18 Gy/6 fractions, maximum 30 Gy/10 fractions) with a maximum cumulative spinal dose of 100 Gy
Trial: 36482193
Drug: Oral rucaparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rucaparib 600 mg twice daily
Trial: 36482216
Drug: SOC +
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOC + additional rifampicin (up to 35 mg/kg/d) + linezolid 1200 mg/d reducing after 28 days to 600 mg/d
Trial: 36482216
Drug: SOC +
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOC + additional rifampicin (up to 35 mg/kg/d) + linezolid 1200 mg/d reducing after 28 days to 600 mg/d + aspirin 1000 mg/d
Trial: 36482352
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly injectable formulation (AOM) for 12 months
Trial: 36482369
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) with pulse amplitudes of 600, 700, and 800 mA
Trial: 36482505
Drug: SARS-CoV-2 anti-spike
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 anti-spike antibody levels in the nose
Trial: 36482505
Drug: Nasal and
RxNorm normalized name: Nasal and Sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal and saliva anti-spike antibody levels
Trial: 36482505
Drug: Plasma anti-spike
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma anti-spike antibody
Trial: 36482505
Drug: SARS-CoV-2 vaccine
RxNorm normalized name: SARS-CoV-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccine given peripherally
Trial: 36482505
Drug: Persistently elevated
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persistently elevated SARS-CoV-2 antibody in plasma
Trial: 36482560
Drug: Efavirenz (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (25 mg/d for 52 weeks)
Trial: 36482815
Drug: Ruxolitinib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (15 mg twice daily) with methylprednisolone (40 mg every other day)
Trial: 36483037
Drug: Therapeutic cancer
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic cancer vaccine containing peptides derived from PD-L1 and PD-L2
Trial: 36483037
Drug: Therapeutic cancer
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic cancer vaccine
Trial: 36483582
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies targeting the PD-1/PD-L1 signaling axis
Trial: 36484484
Drug: ChAd155-RSV (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd155-RSV (low dose)
Trial: 36484484
Drug: ChAd155-RSV (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd155-RSV (medium dose)
Trial: 36484484
Drug: ChAd155-RSV (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd155-RSV (high dose)
Trial: 36485070
Drug: Intraperitoneal/intravenous (IP/IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal/intravenous (IP/IV) chemotherapy in HTB subgroup
Trial: 36485070
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) chemotherapy in HTB subgroup
Trial: 36485070
Drug: Intraperitoneal/intravenous (IP/IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal/intravenous (IP/IV) chemotherapy in LTB subgroup
Trial: 36485070
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) chemotherapy in LTB subgroup
Trial: 36493463
Drug: G-computation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-computation
Trial: 36493603
Drug: Self-assessment using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-assessment using a tablet application for detecting herb and food-drug interactions (HFDIs).
Trial: 36494748
Drug: Ongoing evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing evidence-based assessments (annual, monthly, daily)
Trial: 36494776
Drug: Assessments of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessments of caregivers' well-being and treatment decision attitudes.
Trial: 36495795
Drug: Reminiscence music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence music therapy (60-minute sessions, twice a week for 4 weeks)
Trial: 36496395
Drug: Serotypes included
RxNorm normalized name: Human adenovirus b serotype 7
DrugBank: Human adenovirus b serotype 7 (DB14410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotypes included in PCV13 vaccine
Trial: 36498818
Drug: Anti-IL-17C monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-IL-17C monoclonal antibody MOR106, administered for up to 12 weeks.
Trial: 36499023
Drug: Insulin-induced hypoglycemia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-induced hypoglycemia (2 mmol/L; 36 mg/dL)
Trial: 36501072
Drug: 1−2 drinks/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1−2 drinks/day (~12−24 g)
Trial: 36502794
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) ibuprofen
Trial: 36503413
Drug: Low-dose aerosolised
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aerosolised Ad5-nCoV
Trial: 36503413
Drug: High-dose aerosolised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aerosolised Ad5-nCoV
Trial: 36503429
Drug: MDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT with 6 months ADT and ARTA (enzalutamide 4×40 mg daily for 6 months)
Trial: 36503505
Drug: Conventional Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Wound Treatment (CWT)
Trial: 36503610
Drug: Nivolumab (PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (PD-1 inhibitor) followed by SBRT (30 Gy in 3 to 5 fractions)
Trial: 36503736
Drug: OCS-01 once
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OCS-01 once daily
Trial: 36504158
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg and 8 mg extended-release tablets
Trial: 36504158
Drug: Fesoterodine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 2 mg and 4 mg extended-release beads-in-capsule (BIC)
Trial: 36504158
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg and 8 mg extended-release tablets and 4 mg BIC
Trial: 36504158
Drug: Oxybutynin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin XL tablets
Trial: 36504291
Drug: Verinurad 24
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad 24 mg extended release with allopurinol 300 mg
Trial: 36504291
Drug: Verinurad 40
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad 40 mg immediate release with allopurinol 300 mg
Trial: 36505793
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (vemurafenib, cobimetinib, and pembrolizumab)
Trial: 36505833
Drug: Lenvatinib 8-12mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 8-12mg once daily and sintilimab 200mg once every three weeks combined with radiotherapy (3Gy*10 fraction)
Trial: 36506562
Drug: SHR7280, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR7280, an oral gonadotropin-releasing hormone antagonist
Trial: 36507677
Drug: Telacebec (Q203)
RxNorm normalized name: Telacebec
DrugBank: Telacebec (DB17754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telacebec (Q203) at doses of 20, 50, 100, 160, 250, and 320 mg, orally administered once daily for 14 days
Trial: 36507686
Drug: Talquetamab (405
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talquetamab (405 μg per kilogram weekly)
Trial: 36507686
Drug: Talquetamab (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talquetamab (800 μg per kilogram every other week)
Trial: 36507690
Drug: Glofitamab monotherapy
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab monotherapy (12 cycles total) after pretreatment with obinutuzumab
Trial: 36507690
Drug: Glofitamab monotherapy
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab monotherapy
Trial: 36507781
Drug: Integrated boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated boost to the dominant intraprostatic nodule in stereotactic body radiation therapy, details on dosage and duration not available.
Trial: 36509053
Drug: Amoxicillin (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (7-day course, standard of care)
Trial: 36509063
Drug: MMV390048 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMV390048 (120 mg)
Trial: 36509097
Drug: Rocatinlimab 150
RxNorm normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocatinlimab 150 mg every 4 weeks
Trial: 36509097
Drug: Rocatinlimab 600
RxNorm normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocatinlimab 600 mg every 4 weeks
Trial: 36509097
Drug: Rocatinlimab 300
RxNorm normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocatinlimab 300 mg every 2 weeks
Trial: 36509097
Drug: Rocatinlimab 600
RxNorm normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocatinlimab 600 mg every 2 weeks
Trial: 36509100
Drug: RO7020531 (doses:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7020531 (doses: 3 mg, 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, 170 mg)
Trial: 36509100
Drug: RO7020531 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7020531 (150 mg, 170 mg)
Trial: 36509100
Drug: RO7020531 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7020531 (150 mg)
Trial: 36509249
Drug: SB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB with twice/h breaks (alternating 5 min walk and 15 min stand)
Trial: 36510290
Drug: Remimazolam tosylate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam tosylate at 0.15 mg/kg
Trial: 36510290
Drug: Remimazolam tosylate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam tosylate at 0.2 mg/kg
Trial: 36510290
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 1.5 mg/kg
Trial: 36510324
Drug: Ultra-lung-protective ventilation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-lung-protective ventilation (1-2 mL/kg tidal volume, 5-10 cycles per minute, positive expiratory transpulmonary pressure, 16 hours of prone position)
Trial: 39103901
Drug: Budesonide/glycopyrronium/formoterol fumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 320/14.4/10 µg
Trial: 36510486
Drug: Budesonide/glycopyrronium/formoterol fumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 160/14.4/10 µg
Trial: 39103901
Drug: Glycopyrronium/formoterol fumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium/formoterol fumarate dihydrate (GFF) 14.4/10 µg
Trial: 39103901
Drug: Budesonide/formoterol fumarate
RxNorm normalized name: budesonide/formoterol fumarate 80/4.5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol fumarate dihydrate (BFF) 320/10 µg
Trial: 36510662
Drug: Neutralization of
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralization of ACBP/DBI through a monoclonal antibody
Trial: 36511191
Drug: BI 695501
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 695501 for the entire 46-week treatment period